drugset / Trial / NCT01005979
A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD), safety and toxicity when cyclophosphamide, rituximab and lenalidomide (Revlimid) are combined for the treatment of relapsed/refractory of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Timeline
- Start
- 2010-07
- Primary completion
- 2012-10
- Completion
- —
Outcome
Outcome not reported
Stopped (Enrollment): “Slow Accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | 2.5 mg | — |
| Subject | Lenalidomide | Other / unclassified | 5 mg | — |
| Subject | Lenalidomide | Other / unclassified | 10 mg | — |
| Subject | Lenalidomide | Other / unclassified | 15 mg | — |
| Background | Cyclophosphamide | Other / unclassified | 250 mg/m2 | — |
| Background | Rituximab | Monoclonal antibody | 500 mg/m2 | Intravenous |